1. Home
  2. ONL vs MOLN Comparison

ONL vs MOLN Comparison

Compare ONL & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONL
  • MOLN
  • Stock Information
  • Founded
  • ONL 2021
  • MOLN 2004
  • Country
  • ONL United States
  • MOLN Switzerland
  • Employees
  • ONL N/A
  • MOLN N/A
  • Industry
  • ONL Real Estate Investment Trusts
  • MOLN
  • Sector
  • ONL Real Estate
  • MOLN
  • Exchange
  • ONL Nasdaq
  • MOLN Nasdaq
  • Market Cap
  • ONL 119.7M
  • MOLN 142.6M
  • IPO Year
  • ONL N/A
  • MOLN 2021
  • Fundamental
  • Price
  • ONL $2.97
  • MOLN $3.74
  • Analyst Decision
  • ONL Hold
  • MOLN
  • Analyst Count
  • ONL 1
  • MOLN 0
  • Target Price
  • ONL N/A
  • MOLN N/A
  • AVG Volume (30 Days)
  • ONL 354.0K
  • MOLN 4.4K
  • Earning Date
  • ONL 08-06-2025
  • MOLN 08-25-2025
  • Dividend Yield
  • ONL 2.69%
  • MOLN N/A
  • EPS Growth
  • ONL N/A
  • MOLN N/A
  • EPS
  • ONL N/A
  • MOLN N/A
  • Revenue
  • ONL $151,869,000.00
  • MOLN $856,302.00
  • Revenue This Year
  • ONL N/A
  • MOLN N/A
  • Revenue Next Year
  • ONL N/A
  • MOLN $1,000.00
  • P/E Ratio
  • ONL N/A
  • MOLN N/A
  • Revenue Growth
  • ONL N/A
  • MOLN N/A
  • 52 Week Low
  • ONL $1.46
  • MOLN $3.36
  • 52 Week High
  • ONL $4.39
  • MOLN $7.60
  • Technical
  • Relative Strength Index (RSI)
  • ONL 75.51
  • MOLN 51.55
  • Support Level
  • ONL $2.52
  • MOLN $3.65
  • Resistance Level
  • ONL $2.85
  • MOLN $4.09
  • Average True Range (ATR)
  • ONL 0.10
  • MOLN 0.18
  • MACD
  • ONL 0.02
  • MOLN 0.02
  • Stochastic Oscillator
  • ONL 91.26
  • MOLN 20.90

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: